FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

TUESDAY, June 5, 2018 -- The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news